Genetic Technologies Announces Financing and Intended Use

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genetic Technologies Announces Financing and Intended Use of Proceeds

MELBOURNE, AUSTRALIA--(Marketwired - Aug 1, 2013) - Genetic Technologies Limited ( ASX : GTG ) ( NASDAQ : GENE )

  • Finalised private placement of shares to domestic and overseas institutional and sophisticated investors raising AUD 2,200,000
  • Proposed Share Purchase Plan ("SPP") to eligible shareholders to raise up to AUD 3,000,000
  • Proposed issue of Redeemable Convertible Notes to an institutional investor to raise USD 5,000,000
  • Commercial roll-out of BREVAGen ™ , the Company's flagship breast cancer risk test, demonstrating growing traction in large U.S. women's health market
  • Combined fund raising, once complete, expected to provide the Company with resources sufficient to achieve its commercial goals in the U.S.

Molecular diagnostics company Genetic Technologies Limited ( ASX : GTG ) ( NASDAQ : GENE ) today announced a private placement of ordinary shares to domestic and overseas institutional and sophisticated investors to raise AUD 2,200,000.

The Company also plans to raise up to an additional AUD 3,000,000 via a share purchase plan ("SPP") to eligible shareholders, and has executed a term sheet providing for the issuance of Redeemable Convertible Notes ("Notes") to an institutional investor, Ironridge Global IV, Ltd. ("Ironridge"), which, when completed, is expected to raise a further USD 5,000,000.

Lodge Corporate Pty. Ltd. acted as Lead Manager on the fund raising with Ladenburg Thalmann & Co. Inc. acting as placement agent on the Notes, which in aggregate will raise up to AUD 10,600,000 (excluding offer costs). Proceeds from the combined fund raising, together with existing cash, will be applied to:

  • expansion of U.S. distribution for the Company's lead breast cancer test, BREVAGen ™ ;
  • completion of additional studies to add new ethnicities (Hispanic and African American) and to expand the addressable market for BREVAGen™;
  • the increase of market awareness for BREVAGen™ through broader and more active key opinion leader and speaker programs;
  • investment to further improve reimbursement performance; and
  • general working capital.

The shares to be offered under the private placement ("Placement") and the SPP will be issued at a price of AUD 0.072 per share, representing a 15.3% discount to the last close price (AUD 0.085) prior to the trading halt on 29 July 2013 (AEST), and a 19.1% discount to the 30-day VWAP (AUD 0.089). The Notes to be issued to Ironridge will be convertible into new NASDAQ-traded American Depository Receipts ("ADRs") at a fixed issue price of USD 3.00 per ADR, representing a 26.1% premium to the last closing pricing of of the ADRs on NASDAQ (USD 2.38) prior to the trading halt.

The combined fund raising will be conducted in three tranches, namely:

1.  Private Placement - AUD 2,200,000

The placement of 30,555,556 new shares at an issue price of AUD 0.072 per share to raise AUD 2,200,000 will be conducted under the Company's current 15% placement capacity in accordance with ASX Listing Rule 7.1 and accordingly shareholder approval for the private placement is not required. The new shares will rank equally with existing shares and settlement under the Placement is expected to occur on 8 August 2013 (AEST). The Placement shares are expected to be allotted and quoted on the Australian Securities Exchange ("ASX") within one business day of settlement.

2.  Share Purchase Plan - AUD 3,000,000

The Company intends to offer a Share Purchase Plan (" SPP " or " Plan ") to eligible shareholders to raise up to a further AUD 3,000,000 on the same terms as the Placement, i.e. at an issue price of AUD 0.072 per share, subject to a waiver being received from the ASX which the Company expects to be granted shortly.

The record date for eligible shareholders to participate in the proposed SPP will be 29 July 2013 (the " Record Date "). Eligible shareholders with a registered address in either Australia or New Zealand will be offered the right to take up to AUD 7,500 worth of fully paid ordinary shares in the Company (" SPP Shares "). Participation in the SPP is optional and available irrespective of the number of shares an Eligible Member currently holds in the Company.

The SPP documents are expected to be despatched to shareholders within 14 days of the Record Date. The SPP offer to eligible shareholders will be non-renounceable and entitlements will not be tradable on the ASX or otherwise transferable. Further details concerning the SPP, including the proposed timetable for the SPP, will be the subject of further ASX announcements in due course.

3.  Redeemable Convertible Notes Issue - USD 5,000,000

The Company has executed a term sheet dated 26 July 2013 setting the terms and conditions pursuant to which the Company will issue convertible notes to Ironridge to raise USD 5,000,000. The issue of the Notes will be subject to shareholder approval which the Company will seek at a General Meeting scheduled for September 2013 (details of which will be released to the ASX at the appropriate time). The issue is also subject to the completion of certain US regulatory requirements which the Company anticipates will be finalised before the end of October 2013.

The proposed Notes will be convertible into new ADRs (as traded on NASDAQ under the ticker: GENE) at a fixed issue price of USD 3.00 per ADR. Ironridge will have an option to subscribe for an additional USD 5,000,000 of Notes on the same terms, but convertible into ADRs at a fixed issue price of USD 4.00 per ADR, at any time within a six-month period of the date of the definitive documents being executed (known as a "Greenshoe option").

The broad terms of the proposed Notes are as follows:

(a) The Notes will be convertible into ADRs at a fixed issue price of USD 3.00 per ADR, and at USD 4.00 per ADR under the Greenshoe option;

(b) Interest on the Notes will be calculated at an annual rate of 7.5% per annum, which is adjustable in accordance with certain share market price changes, and will accrue until either the conversion or redemption of the Notes;

(c) The Notes do not have a fixed expiry date and may be redeemed for cash by the Company at any time, or converted into ADRs by the Purchaser or (subject to certain conditions) into ADRs by the Company;

(d) The issue and subscription for the Notes is subject to various conditions precedent including the receipt of shareholder approval, registration of the ADRs and ensuring there are sufficient ADRs available for the conversion of the Notes, delivery of certain opinion letters and additional customary equity funding conditions; and

(e) The Noteholder does not have any right to vote at shareholder meetings.

Commenting on the combined fund raising, GTG Chief Executive Officer, Ms. Alison Mew said: "The additional funding, combined with our existing cash reserves and building recurring income streams, should provide the platform to create a vital and sustainable global molecular diagnostics company."

Genetic Technologies confirms that, with the release of this announcement, the Company is in full compliance with its continuous disclosure obligations.

About Genetic Technologies Limited Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (Deoxyribonucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species. Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio. Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit www.gtglabs.com .

Safe Harbor Statement Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

FOR FURTHER INFORMATION PLEASE CONTACT Ms. Alison J. Mew Chief Executive Officer Genetic Technologies Limited Phone: +61 3 8412 7000 Laura Forman (USA) Blueprint Life Science Group +1 (415) 375 3340 , Ext. 103 Genetic Technologies Limited Website : www.gtglabs.com Email : info@gtglabs.com ABN 17 009 212 328 Registered Office 60-66 Hanover Street Fitzroy Victoria 3065 Australia Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 Fax +61 3 8412 7040

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 70

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 155

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 108

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 142

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Natural Hydrogen: MAX Power Mining's Vision

Updated Category News Views 184

MAX Power Mining Corp. Driving Innovation in Natural Hydrogen In an era where energy demands are escalating, especially with the rise of artificial intelligence and advanced technologies, the search for sustainable power sources has reached new heights. Enter MAX Power Mining Corp. (OTC: MAXXF) (CSE: MAXX), a trailblazer in the natural hydrogen sector, demonstrating...

Continue Reading
Inland Empire Health Plan Achieves Excellence in GIS Recognition

Updated Category News Views 246

A Celebration of Achievement for Inland Empire Health Plan Inland Empire Health Plan (IEHP) has achieved remarkable recognition by winning its third Special Achievement in GIS (SAG) award from Esri, the global leader in Geographic Information System (GIS) technology. This prestigious accolade highlights IEHP's commitment to utilizing innovative technology to enhance...

Continue Reading
Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge

Updated Category News Views 226

Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge In a groundbreaking moment for sustainable food technology, Ryp Labs was announced as the standout winner of Lineage's prestigious innovation challenge aimed at transforming the global food supply chain. The challenge focused on innovative solutions that address pressing issues such as food waste and supply...

Continue Reading
Future Landscape of the UV Stabilizers Market by 2032

Updated Category News Views 176

Growth of the UV Stabilizers Market The UV stabilizers market is gaining momentum, projected to expand from USD 1.4 billion to USD 2.3 billion by 2032, with a compound annual growth rate (CAGR) of 5.5% during the 2024-2032 period. This growth is fueled by the increasing demand for materials that are durable and can endure the degrading effects of ultraviolet (UV)...

Continue Reading
Dr. Rushika Fernandopulle Joins Premera Board of Directors

Updated Category News Views 337

Dr. Rushika Fernandopulle Joins Premera's Board Premera Blue Cross is excited to announce the addition of Dr. Rushika Fernandopulle to its Board of Directors. This decision is part of a strategic effort to strengthen leadership and expertise within the organization. Dr. Fernandopulle takes over from Dr. John Jenrette, who has completed his term this year. Expertise and...

Continue Reading